Nucleic Acid Extraction System

Suzhou, Jiangsu, China

Suzhou Molarray Co., Ltd. is a high-tech enterprise focusing on the molecular diagnosis, genetic testing technology and microbial testing technology. It was established in September 2010, with nearly 30,000 square meters of production workshop. And it's located in Biobay, a national Biomedical Industrial Park in Suzhou, China. By 2016, a research and development center in Canada and a marketing center in Shanghai were also established to realize the integration of research, production and sales. Suzhou Molarray Co., Ltd. is committed to exploring the application field of gene technology and developing products by relying on its own technical advantages. After 20 years of unremitting efforts, it has formed a series of products and technology matrix. The company's main products include nucleic acid extraction and purification instrument, PCR instrument series (fluorescence quantitative PCR instrument, portable/isothermal quantitative PCR instrument, automatic fluorescence quantitative PCR detection system, qPCR array chip), workstation (dispensing and adding sample processing system, nucleic acid extraction automation workstation, automated PCR workstation and integrated nucleic acid analyzer) and component series, etc. Molarray has accumulated rich experience in research and development in automation control, image processing, optical detection, microscopy, liquid circuits, electronic applications and software, and has more than 40 global patents and about 20 software copyrights. The company has production licenses, sales and business licenses for all medical devices on sale, among which the Class III medical devices have passed the ISO9001 and ISO13485 quality management systems. In the future, Molarray will continue to upgrade the Gene Detection Technology Platform and Nucleic Acid Extraction Technology based on the independent technologies in the areas of automation control, image processing, optical detection, microscopy, liquid circuit, electronic application and software , and continue to track the layout of new technologies, so that the company maintains a high level of overall technical strength. In the meanwhile, relying on our own technology platform to further improve the PCR molecular diagnostic instruments and reagents, increase the expansion into the field of pediatric immunometabolism and consumer-grade genetic testing, accelerate the industrialization of new products, provide a complete set of advanced solutions for the field of nucleic acid testing, and actively create the integrated product system of instruments reagents consumables strengthens the competitive advantage and maintains the market leading position in the field of PCR molecular diagnosis. We will rely on our own technology, products, management and innovation spirit, follow a high-standard quality management system, and build the company into a comprehensive biotechnology company with nucleic acid detection as the core and coexistence of various products and services.